Antibody-mediated rejection: New approaches in prevention and management

R. A. Montgomery, A. Loupy, Dorry Segev

Research output: Contribution to journalArticle

Abstract

Despite the success of desensitization protocols, antibody-mediated rejection (AMR) remains a significant contributor to renal allograft failure in patients with donor-specific antibodies. Plasmapheresis and high-dose intravenous immunoglobulin have proved to be effective treatments to prevent and treat AMR, but irreversible injury in the form of transplant glomerulopathy can commonly manifest months to years later. There is an unmet need to improve the outcomes for patients at risk for AMR. Updated Banff criteria now take into account the increasing understanding of the complex and heterogeneous nature of AMR phenotypes, including the timing of rejection, subclinical and chronic AMR, C4d-negative AMR, and antibody-mediated vascular rejection. Treatment for AMR is not standardized, and there is little in the way of evidence-based treatment guidelines. Refining more precisely the mechanisms of injury responsible for different AMR phenotypes and establishing relevant surrogate endpoints to facilitate more informative studies will likely allow for more accurate determination of prognosis and efficacious intervention using new therapeutic approaches. In addition to plasma exchange and intravenous immunoglobulin, a number of other add-on therapies have been tried in small studies without consistent benefit, including anti-CD20, proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (called IdeS).

Original languageEnglish (US)
Pages (from-to)3-17
Number of pages15
JournalAmerican Journal of Transplantation
Volume18
DOIs
StatePublished - Jan 1 2018

Fingerprint

Antibodies
Intravenous Immunoglobulins
Complement Inactivating Agents
Phenotype
Therapeutics
Interleukin-6 Receptors
Proteasome Inhibitors
Plasma Exchange
Plasmapheresis
Streptococcus pyogenes
Wounds and Injuries
Renal Insufficiency
Allografts
Blood Vessels
Immunoglobulin G
Biomarkers
Tissue Donors
Guidelines
Transplants
Enzymes

Keywords

  • antibody-mediated (ABMR)
  • autoantibody
  • basic (laboratory) research/science
  • clinical research/practice
  • kidney transplantation/nephrology
  • liver transplantation/hepatology
  • organ procurement and allocation, rejection:

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Antibody-mediated rejection : New approaches in prevention and management. / Montgomery, R. A.; Loupy, A.; Segev, Dorry.

In: American Journal of Transplantation, Vol. 18, 01.01.2018, p. 3-17.

Research output: Contribution to journalArticle

@article{ccebbb44ff194595b1fca0d83aca0f52,
title = "Antibody-mediated rejection: New approaches in prevention and management",
abstract = "Despite the success of desensitization protocols, antibody-mediated rejection (AMR) remains a significant contributor to renal allograft failure in patients with donor-specific antibodies. Plasmapheresis and high-dose intravenous immunoglobulin have proved to be effective treatments to prevent and treat AMR, but irreversible injury in the form of transplant glomerulopathy can commonly manifest months to years later. There is an unmet need to improve the outcomes for patients at risk for AMR. Updated Banff criteria now take into account the increasing understanding of the complex and heterogeneous nature of AMR phenotypes, including the timing of rejection, subclinical and chronic AMR, C4d-negative AMR, and antibody-mediated vascular rejection. Treatment for AMR is not standardized, and there is little in the way of evidence-based treatment guidelines. Refining more precisely the mechanisms of injury responsible for different AMR phenotypes and establishing relevant surrogate endpoints to facilitate more informative studies will likely allow for more accurate determination of prognosis and efficacious intervention using new therapeutic approaches. In addition to plasma exchange and intravenous immunoglobulin, a number of other add-on therapies have been tried in small studies without consistent benefit, including anti-CD20, proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (called IdeS).",
keywords = "antibody-mediated (ABMR), autoantibody, basic (laboratory) research/science, clinical research/practice, kidney transplantation/nephrology, liver transplantation/hepatology, organ procurement and allocation, rejection:",
author = "Montgomery, {R. A.} and A. Loupy and Dorry Segev",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ajt.14584",
language = "English (US)",
volume = "18",
pages = "3--17",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Antibody-mediated rejection

T2 - New approaches in prevention and management

AU - Montgomery, R. A.

AU - Loupy, A.

AU - Segev, Dorry

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Despite the success of desensitization protocols, antibody-mediated rejection (AMR) remains a significant contributor to renal allograft failure in patients with donor-specific antibodies. Plasmapheresis and high-dose intravenous immunoglobulin have proved to be effective treatments to prevent and treat AMR, but irreversible injury in the form of transplant glomerulopathy can commonly manifest months to years later. There is an unmet need to improve the outcomes for patients at risk for AMR. Updated Banff criteria now take into account the increasing understanding of the complex and heterogeneous nature of AMR phenotypes, including the timing of rejection, subclinical and chronic AMR, C4d-negative AMR, and antibody-mediated vascular rejection. Treatment for AMR is not standardized, and there is little in the way of evidence-based treatment guidelines. Refining more precisely the mechanisms of injury responsible for different AMR phenotypes and establishing relevant surrogate endpoints to facilitate more informative studies will likely allow for more accurate determination of prognosis and efficacious intervention using new therapeutic approaches. In addition to plasma exchange and intravenous immunoglobulin, a number of other add-on therapies have been tried in small studies without consistent benefit, including anti-CD20, proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (called IdeS).

AB - Despite the success of desensitization protocols, antibody-mediated rejection (AMR) remains a significant contributor to renal allograft failure in patients with donor-specific antibodies. Plasmapheresis and high-dose intravenous immunoglobulin have proved to be effective treatments to prevent and treat AMR, but irreversible injury in the form of transplant glomerulopathy can commonly manifest months to years later. There is an unmet need to improve the outcomes for patients at risk for AMR. Updated Banff criteria now take into account the increasing understanding of the complex and heterogeneous nature of AMR phenotypes, including the timing of rejection, subclinical and chronic AMR, C4d-negative AMR, and antibody-mediated vascular rejection. Treatment for AMR is not standardized, and there is little in the way of evidence-based treatment guidelines. Refining more precisely the mechanisms of injury responsible for different AMR phenotypes and establishing relevant surrogate endpoints to facilitate more informative studies will likely allow for more accurate determination of prognosis and efficacious intervention using new therapeutic approaches. In addition to plasma exchange and intravenous immunoglobulin, a number of other add-on therapies have been tried in small studies without consistent benefit, including anti-CD20, proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (called IdeS).

KW - antibody-mediated (ABMR)

KW - autoantibody

KW - basic (laboratory) research/science

KW - clinical research/practice

KW - kidney transplantation/nephrology

KW - liver transplantation/hepatology

KW - organ procurement and allocation, rejection:

UR - http://www.scopus.com/inward/record.url?scp=85039919051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039919051&partnerID=8YFLogxK

U2 - 10.1111/ajt.14584

DO - 10.1111/ajt.14584

M3 - Article

C2 - 29292861

AN - SCOPUS:85039919051

VL - 18

SP - 3

EP - 17

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -